Evaluating a Stone of Hope: ICER's 2019 Review of Treatments for Duchenne Muscular Dystrophy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32223600.
- Also identified by DOI 10.18553/jmcp.2020.26.4.366 and PMC identifier 10390954.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No funding contributed to the writing of this commentary. Brandsema reports consulting for Alexion, Audentes, AveXis, Biogen, Cytokinetics, PTC Therapeutics, Sarepta, and WaVe and has received research funding as a site investigator from Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta, Summit, and WaVe.
Medical subject headings
- Insurance Coverage
- Insurance, Pharmaceutical Services
- Morpholinos
- Muscular Dystrophy, Duchenne
- Oligonucleotides
- Pregnenediones